Compass Pathways PLC (FRA:5Y6)
€ 4.26 0 (0%) Market Cap: 291.47 Mil Enterprise Value: 126.62 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 38/100

Compass Pathways PLC at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 02:10PM GMT
Release Date Price: €11.15 (+17.37%)
Ritu Baral
Cowen and Company, LLC - Analyst

Good morning, everyone. Thank you so much for joining us today at the Cowen Health Care Conference Neuropsychiatry Corporate Panel. With us today on the panel, we have Andy Kidd, CEO of Aptinyx; we have CMO of atai, Rolando Gutierrez; we have CMO of COMPASS, Guy Goodwin; CEO of GH Research, Theis Terwey; and CEO of Praxis, Marcio Souza. Thanks, guys, for joining us today.

Questions & Answers

Ritu Baral
Cowen and Company, LLC - Analyst

We are going to start with some neuropsychiatry thematic questions, questions that span all -- multiple, if not all of the companies, and then we'll go to sort of mini fireside chats for the individual companies with the time that we have remaining. We are going to start with the bogeyman of all depression studies, really all neuropsychiatry studies' placebo effect. You all have neuropsychiatry, either PTSD or depression studies underway where you are going to be looking at placebo.

Why do these rates keep rising? Is it anticipation? Is it just conduct patient

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot